ISB 2001
Alternative Names: ISB-2001; TREAT™ trispecific antibody - Ichnos SciencesLatest Information Update: 17 Jun 2024
At a glance
- Originator Ichnos Sciences
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Multiple myeloma
- Preclinical Haematological malignancies
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Multiple myeloma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 30 Jan 2024 Glenmark and Ichnos entered into an alliance 'Ichnos Glenmark Innovation' to accelerate new drug discovery in cancer treatment
- 02 Nov 2023 The Human Research Ethics Committee approves clinical trial application for ISB 2001 in Multiple myeloma in Australia, before November 2023